Porcine cardiac xenograft valves: analysis of survival, valve failure, and explantation.
Porcine cardiac xenografts were used for cardiac valve replacement in 1,093 patients. Hospital mortality for aortic valve replacement (AVR) was 3.7%; for mitral valve replacement (MVR), 7.8%; and for AVR + MVR, 4.7%. Total follow-up was 2,036 patient-years; maximum, 7.3 years; and mean, 1.89 years. Actuarial survival (+/- standard error of the mean) for AVR was 84% +/- 2% at 56 months; for MVR, 84% +/- 3% at 56 months; and for AVR + MVR, 86% +/- 4% at 30 months. Nonfatal thromboembolism occurred in 8 of 1,030 patients (0.78%). Anticoagulation was not routinely employed. Fifty hospital survivors (4.8%) experienced valve dysfunction; 18 of the survivors (1.7%) died; and 32 of the survivors (3.1%) underwent reoperation. The rate of dysfunction increased slowly until the sixth year when an increased rate was observed (p less than 0.0001). Patients less than 34 years old had a higher incidence of dysfunction (p less than 0.01). Thirty-two hospital survivors (3.1%) underwent explantation of the porcine valve for late dysfunction. Valve dysfunction secondary to endocarditis and paravalvular leak occurred early, while leaflet deterioration or thrombosis was more gradual in onset and was noted later. The porcine valve has functioned well for 1 to 7 years with a low incidence of valve related morbidity and mortality without routine anticoagulation in patients older than 34 years of age.
D001021:Aortic Valve / Q000601:surgery; D001705:Bioprosthesis / Q000009:adverse effects / Q000401:mortality; D004696:Endocarditis / Q000209:etiology; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D008943:Mitral Valve / Q000601:surgery; D011183:Postoperative Complications; D013923:Thromboembolism / Q000209:etiology